Organizations Filed Purposes:
THE MISSION OF QUANTUM LEAP HEALTHCARE COLLABORATIVE IS TO PROVIDE MANAGEMENT AND FINANCIAL SUPPORT TO HEALTHCARE RESEARCH ORGANIZATIONS, PARTICULARLY INVOLVING BREAST CANCER RESEARCH AND TREATMENT.
I-SPY TRIALS: QUANTUM LEAP SPONSORS THE I-SPY TRIALS (INVESTIGATION OF SERIAL STUDIES TO PREDICT YOUR THERAPEUTIC RESPONSE WITH IMAGING AND MOLECULAR ANALYSIS). I-SPY HAS BEEN RE-ENGINEERING THE APPROACH TO CLINICAL TRIALS, WITH A GOAL OF GETTING THE RIGHT DRUG TO THE RIGHT PATIENT AT THE TIME WHEN THEY WILL BENEFIT MOST, AND TO ACHIEVE THIS FASTER THAN POSSIBLE IN PREVIOUS TRIAL MODELS. ADDITIONALLY, I-SPY AIMS TO SIGNIFICANTLY REDUCE THE OVERALL COST, TIME, AND NUMBER OF PATIENTS REQUIRED TO BRING NEW DRUGS TO MARKET. THE I-SPY TRIAL PROGRAM INTEGRATES AND LINKS PHASE I (I-SPY PHASE 1), PHASE II (I-SPY 2), AND FUTURE PHASES TO BUILD A PIPELINE OF NOVEL AGENTS AND ACCELERATE THE PROCESS OF IDENTIFYING THE SUBSET OF HIGH RISK BREAST CANCER PATIENTS THAT WILL BENEFIT FROM THESE NEW AGENTS, AND GET THESE DRUG INTO THE CLINIC IN A TIMELY MANNER.
COLLABORATION WITH THE ATHENA BREAST HEALTH NETWORK: THE ATHENA BREAST HEALTH NETWORK IS A COLLABORATION OF THE FIVE UNIVERSITY OF CALIFORNIA MEDICAL CENTERS AND SANFORD HEALTH TO DRIVE INNOVATION IN BREAST CANCER PREVENTION, SCREENING AND TREATMENT. A LARGE-SCALE DEMONSTRATION PROJECT, ATHENA INTEGRATES CLINICAL CARE AND RESEARCH TO DRIVE INNOVATION IN PREVENTION, SCREENING, TREATMENT AND MANAGEMENT OF BREAST CANCER.THIS PROJECT WILL IMPROVE SURVIVAL AND REDUCE SUFFERING FROM BREAST CANCER BY ACCELERATING THE TIME BETWEEN RESEARCH DISCOVERIES AND INNOVATIVE PATIENT TREATMENTS. MAJOR INITIATIVES INCLUDE RISK ASSESSMENT AND EVALUATION, RADIOLOGY HARMONIZATION, PATHOLOGY HARMONIZATION, AND IMPROVING SURVIVORSHIP CARE. ONE OF ATHENA'S CURRENT INITIATIVES IS THE WISDOM STUDY. THIS FIVE-YEAR STUDY WILL INVOLVE APPROXIMATELY 100,000 WOMEN 40 TO 80 YEARS OLD. IT WILL TEST A MORE TARGETED APPROACH TO BREAST CANCER SCREENING: THOSE AT HIGHER RISK ARE SCREENED MORE OFTEN AND THOSE AT LOWER RISK ARE SCREENED LESS OFTEN. ANNUAL SCREENING WILL BE WEIGHED AGAINST A PERSONALIZED SCHEDULE OF SCREENING BASED ON EACH WOMAN'S INDIVIDUAL RISK.QUANTUM LEAP PROVIDES IT AND SOFTWARE DEVELOPMENT SUPPORT, MARKETING SUPPORT, AND FUNDRAISING ASSISTANCE FOR THE ATHENA BREAST HEALTH NETWORK.
ONESOURCE: THE INITIATIVE SEEKS TO INTEGRATE CARE AND RESEARCH BY STREAMLINING THE COLLECTION AND DISTRIBUTION OF PATIENT HEALTH DATA. HEALTH INDUSTRIES TODAY ARE CHARACTERIZED BY HIGH OPERATING COSTS WITH VERY LITTLE CORRESPONDING IMPROVEMENT IN QUALITY OF CARE OR MEANINGFUL SCIENTIFIC DISCOVERIES. AT THE HEART OF THE PROBLEM ARE THE LACK OF DATA RECONCILIATION, THE COMPLEXITY OF SYSTEMS INTEGRATIONS, AND THE ABUNDANCE OF INTEROPERABILITY GAPS. AS A RESULT, DOCTORS, RESEARCHERS, AND PATIENTS ARE TRAPPED IN AN INEFFICIENT SYSTEM THAT NOT ONLY GENERATES HIGH COSTS, BUT ALSO INCREASES COMPLIANCE RISK AND CREATE BARRIERS TO CLINICAL TRIAL PARTICIPATION.ONESOURCE IS A RADICAL SIMPLIFICATION THAT WILL UTILIZE GLOBAL DATA STANDARDS IN ORDER TO INTEGRATE CLINICAL CARE AND RESEARCH. IN THE ONESOURCE APPROACH, CRITICAL CLINICAL DATA IS ENTERED ONCE AT THE POINT OF CARE - THE DOCTOR'S APPOINTMENT, FOR EXAMPLE - AND ACCESSIBLE TO MANY. BY IMPLEMENTING BEST-IN-CLASS INTEROPERABLE SYSTEMS AND LEVERAGING EXISTING CAPABILITIES AND RELATIONSHIPS TO FACILITATE THE COLLECTION, SHARING, AND REPORTING OF STRUCTURED DATA FROM AUTHORITATIVE SOURCES, ULTIMATELY ONESOURCE WILL CREATE A QUALITY MANAGEMENT INFRASTRUCTURE IN MEDICINE THAT CAN ENABLE USERS TO IMPROVE HEALTH CARE QUALITY, ACCELERATE CLINICAL RESEARCH, AND ADVANCE HEALTHCARE VALUE.QUANTUM LEAP IS WORKING WITH RESEARCH AND EDUCATIONAL INSTITUTIONS, AS WELL AS COMMERCIAL ENTITIES, TO UTILIZE THE ONESOURCE DATA PLATFORM TO SUPPORT PATIENT AND PROVIDER PORTALS THROUGH ELECTRONIC DATA CAPTURE, WITH THE INTENT TO CREATE INTERACTIVE HEALTH CARE MANAGEMENT SYSTEMS THAT PROVIDE COMPREHENSIVE INFORMATION FOR IMPROVED PATIENT CARE.
Executives Listed on Filing
Total Salary includes financial earnings, benefits, and all related organization earnings listed on tax filing
| Name | Title | Hours Per Week | Total Salary |
|---|
| Karyn Digiorgio | COO | 40 | $217,264 |
| Dave Mandelkern | CHAIRMAN | 24 | $204,882 |
| Kathryn J Watson-Feiner | DIRECTOR OF FINANCE | 40 | $174,000 |
| Tracey L Heather | DIRECTOR OF DEVELOPMENT | 40 | $162,838 |
| Michael Resendez | SENIOR SOFTWARE ENGINEER | 40 | $147,499 |
| Adam Asare | CHIEF DATA OFFICER | 40 | $147,458 |
| James Palazzolo | CEO (FROM 9/2019) | 40 | $96,253 |
| Lambert Van Der Walde | DIRECTOR | 0.5 | $0 |
| N Marcus Thygeson | DIRECTOR | 0.5 | $0 |
| Mark Simon | DIRECTOR | 0.5 | $0 |
| Gregory C Simon | DIRECTOR | 0.5 | $0 |
| Robyn Lawrie Rutledge | DIRECTOR | 0.5 | $0 |
| Robert Patterson | DIRECTOR | 0.5 | $0 |
| Michele Markus | DIRECTOR | 0.5 | $0 |
| Susan Foley | TREASURER | 0.5 | $0 |
| Lucas Debreed | DIRECTOR | 0.5 | $0 |
| Anna Barker | DIRECTOR | 0.5 | $0 |
| Jeffrey Pfeffer | DIRECTOR, COFOUNDER | 0.5 | $0 |
| Laura Esserman | DIRECTOR, COFOUNDER | 20 | $0 |
Data for this page was sourced from XML published by IRS (
public 990 form dataset) from:
https://s3.amazonaws.com/irs-form-990/202013169349305526_public.xml